For example, the FDA has approved the combination of atezolizumab, an anti-programmed death ligand (PD-L1) antibody, plus bevacizumab (anti-VEGF antibody) in the first-line setting because it is associated with a median OS of 19 months in patients with advanced HCC [6–8]. Here, CD274 is linked to hepatocellular carcinoma.